PortalPublikationenSuccessful HCV eradication and inhibition of HIV replication...

Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient

Standard

Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. / Payer, B A; Reiberger, T; Rutter, K; Beinhardt, S; Staettermayer, A F; Peck-Radosavljevic, M; Ferenci, P.

in: J CLIN VIROL, Jahrgang 49, Nr. 2, 01.10.2010, S. 131-3.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Payer, BA, Reiberger, T, Rutter, K, Beinhardt, S, Staettermayer, AF, Peck-Radosavljevic, M & Ferenci, P 2010, 'Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient', J CLIN VIROL, Jg. 49, Nr. 2, S. 131-3. https://doi.org/10.1016/j.jcv.2010.07.006

APA

Payer, B. A., Reiberger, T., Rutter, K., Beinhardt, S., Staettermayer, A. F., Peck-Radosavljevic, M., & Ferenci, P. (2010). Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J CLIN VIROL, 49(2), 131-3. https://doi.org/10.1016/j.jcv.2010.07.006

Vancouver

Payer BA, Reiberger T, Rutter K, Beinhardt S, Staettermayer AF, Peck-Radosavljevic M et al. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J CLIN VIROL. 2010 Okt 1;49(2):131-3. https://doi.org/10.1016/j.jcv.2010.07.006

Bibtex

@article{c9d04c8c4eaf4113adedcca18810ea8b,
title = "Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient",
abstract = "INTRODUCTION: The efficacy of antiviral therapy with pegylated interferon (PEGIFN) plus ribavirin (RBV) in patients with HIV and hepatitis C virus (HCV) coinfection is limited. Intravenous silibinin (ivSIL), a milk thistle extract with proven antiviral effects represents a novel therapeutic strategy for virological nonresponders.METHODS: We report a case of an HIV-HCV coinfected patient, who has not responded to a prior course of PEGIFN-α2a (180 μg/week/s.c.) and RBV (1000 mg/day/p.o.). Testing for IL-28β small nucleotid polymorphism revealed the nonfavourable genotype T/T. Antiretroviral therapy was not prescribed because the patients presented with well-preserved CD4+ cell counts and low HIV-RNA levels. She received retreatment with ivSIL for two weeks followed by PEGIFN/RBV combination therapy starting at week 1.RESULTS: After 2 weeks of ivSIL therapy both HCV-RNA and HIV-RNA become undetectable. On ivSIL monotherapy we noticed a trend towards an increase of CD4+ cell counts and a decrease of HIV-RNA. After 16 weeks PEGIFN+RBV was discontinued due to patients wish because of adverse events. HCV-RNA was still negative 24 weeks after cessation of therapy, while HIV-RNA returned to baseline levels.CONCLUSION: ivSIL may represent a potential treatment option for retreatment of HIV-HCV coinfected patients nonresponding to PEGIFN+RBV combination therapy. Further investigations on the possible beneficial effects of ivSIL on CD4+ cell counts and HIV-RNA levels are necessary.",
keywords = "Adult, Antiviral Agents, CD4 Lymphocyte Count, Female, HIV, HIV Infections, Hepacivirus, Hepatitis C, Chronic, Humans, Interferon-alpha, Polyethylene Glycols, RNA, Viral, Recombinant Proteins, Ribavirin, Silymarin, Treatment Outcome, Viral Load",
author = "Payer, {B A} and T Reiberger and K Rutter and S Beinhardt and Staettermayer, {A F} and M Peck-Radosavljevic and P Ferenci",
note = "Copyright {\textcopyright} 2010 Elsevier B.V. All rights reserved.",
year = "2010",
month = oct,
day = "1",
doi = "10.1016/j.jcv.2010.07.006",
language = "English",
volume = "49",
pages = "131--3",
journal = "J CLIN VIROL",
issn = "1386-6532",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient

AU - Payer, B A

AU - Reiberger, T

AU - Rutter, K

AU - Beinhardt, S

AU - Staettermayer, A F

AU - Peck-Radosavljevic, M

AU - Ferenci, P

N1 - Copyright © 2010 Elsevier B.V. All rights reserved.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - INTRODUCTION: The efficacy of antiviral therapy with pegylated interferon (PEGIFN) plus ribavirin (RBV) in patients with HIV and hepatitis C virus (HCV) coinfection is limited. Intravenous silibinin (ivSIL), a milk thistle extract with proven antiviral effects represents a novel therapeutic strategy for virological nonresponders.METHODS: We report a case of an HIV-HCV coinfected patient, who has not responded to a prior course of PEGIFN-α2a (180 μg/week/s.c.) and RBV (1000 mg/day/p.o.). Testing for IL-28β small nucleotid polymorphism revealed the nonfavourable genotype T/T. Antiretroviral therapy was not prescribed because the patients presented with well-preserved CD4+ cell counts and low HIV-RNA levels. She received retreatment with ivSIL for two weeks followed by PEGIFN/RBV combination therapy starting at week 1.RESULTS: After 2 weeks of ivSIL therapy both HCV-RNA and HIV-RNA become undetectable. On ivSIL monotherapy we noticed a trend towards an increase of CD4+ cell counts and a decrease of HIV-RNA. After 16 weeks PEGIFN+RBV was discontinued due to patients wish because of adverse events. HCV-RNA was still negative 24 weeks after cessation of therapy, while HIV-RNA returned to baseline levels.CONCLUSION: ivSIL may represent a potential treatment option for retreatment of HIV-HCV coinfected patients nonresponding to PEGIFN+RBV combination therapy. Further investigations on the possible beneficial effects of ivSIL on CD4+ cell counts and HIV-RNA levels are necessary.

AB - INTRODUCTION: The efficacy of antiviral therapy with pegylated interferon (PEGIFN) plus ribavirin (RBV) in patients with HIV and hepatitis C virus (HCV) coinfection is limited. Intravenous silibinin (ivSIL), a milk thistle extract with proven antiviral effects represents a novel therapeutic strategy for virological nonresponders.METHODS: We report a case of an HIV-HCV coinfected patient, who has not responded to a prior course of PEGIFN-α2a (180 μg/week/s.c.) and RBV (1000 mg/day/p.o.). Testing for IL-28β small nucleotid polymorphism revealed the nonfavourable genotype T/T. Antiretroviral therapy was not prescribed because the patients presented with well-preserved CD4+ cell counts and low HIV-RNA levels. She received retreatment with ivSIL for two weeks followed by PEGIFN/RBV combination therapy starting at week 1.RESULTS: After 2 weeks of ivSIL therapy both HCV-RNA and HIV-RNA become undetectable. On ivSIL monotherapy we noticed a trend towards an increase of CD4+ cell counts and a decrease of HIV-RNA. After 16 weeks PEGIFN+RBV was discontinued due to patients wish because of adverse events. HCV-RNA was still negative 24 weeks after cessation of therapy, while HIV-RNA returned to baseline levels.CONCLUSION: ivSIL may represent a potential treatment option for retreatment of HIV-HCV coinfected patients nonresponding to PEGIFN+RBV combination therapy. Further investigations on the possible beneficial effects of ivSIL on CD4+ cell counts and HIV-RNA levels are necessary.

KW - Adult

KW - Antiviral Agents

KW - CD4 Lymphocyte Count

KW - Female

KW - HIV

KW - HIV Infections

KW - Hepacivirus

KW - Hepatitis C, Chronic

KW - Humans

KW - Interferon-alpha

KW - Polyethylene Glycols

KW - RNA, Viral

KW - Recombinant Proteins

KW - Ribavirin

KW - Silymarin

KW - Treatment Outcome

KW - Viral Load

U2 - 10.1016/j.jcv.2010.07.006

DO - 10.1016/j.jcv.2010.07.006

M3 - SCORING: Journal article

C2 - 20709593

VL - 49

SP - 131

EP - 133

JO - J CLIN VIROL

JF - J CLIN VIROL

SN - 1386-6532

IS - 2

ER -